Myricx Pharma (private company)

See something wrong or missing? Let us know
Offices:
London
Business model:
B2B
Investors:
we tracked 2 investors
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 1 transaction

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Myricx Pharma is a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer

Companies with similar profile to Myricx Pharma:

CompanyCriteria
Denmark AFYX Therapeutics
56%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one vc investor: Sofinnova Partners
  • Minim one investor from outside Scandinavia: Yes
Sweden EnginZyme
55%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: Sofinnova Partners
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Spain Oncomatryx
54%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
France Synapse Medicine
54%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Germany Aignostics
54%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Germany Semalytix
54%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Spain Amadix
54%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Spain Ability Pharma
54%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
France AbolerIS Pharma
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Spain Sanifit Therapeutics
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Norway Curida
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
Denmark Biosyntia
44%
  • Similar business models: B2B
  • At least one vc investor: Sofinnova Partners
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Sweden OnDosis
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Spain Bigfinite
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark NMD Pharma
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Switzerland T3 Pharmaceuticals
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Netherlands Citryll
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Sweden Asarina Pharma
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Switzerland Pharvaris
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
France Owkin
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes